# Ertugliflozin: Cardioprotective Effects on Epicardial Fat

> **NCT04167761** · EARLY_PHASE1 · COMPLETED · sponsor: **Stanford University** · enrollment: 61 (actual)

## Conditions studied

- Cardiovascular Diseases
- Atherosclerosis
- Type 2 Diabetes
- Insulin Resistance

## Interventions

- **DRUG:** Ertugliflozin

## Key facts

- **NCT ID:** NCT04167761
- **Lead sponsor:** Stanford University
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-07-01
- **Primary completion:** 2023-12-31
- **Final completion:** 2023-12-31
- **Target enrollment:** 61 (ACTUAL)
- **Last updated:** 2024-12-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04167761

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04167761, "Ertugliflozin: Cardioprotective Effects on Epicardial Fat". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04167761. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*